Hormone Therapy Timing & Heart Risk
study3_post04  |  image: study3_post04_clinical.png
------------------------------------------------------------------------

ON THE IMAGE
Oral and transdermal don't behave the same way

CAPTION
A detail that gets flattened in most coverage: how hormone therapy is delivered changes what it does.

Oral estrogens undergo hepatic first-pass metabolism, which stimulates production of coagulation factors. Transdermal delivery bypasses that route, and studies commonly show a neutral or favorable effect on blood pressure and clot risk.

Much of the older evidence that shaped public fear tested one oral formulation, in older women.

Questions about what this means for you? Call [Practice Name] at [Phone] or book at [Booking Link].

Educational content, not medical advice — individual results and risks vary.

HASHTAGS
#menopause #womenshealth #hearthealth #hormonetherapy #midlifewomen

SUPPORTING EVIDENCE
Risk stratification section: oral oestrogens undergo hepatic first-pass metabolism; transdermal bypasses hepatic metabolism, minimizing these effects.
